Defining a common region of deletion at 13q21 in human cancers

Ceshi Chen, Will W. Brabham, Brian G. Stultz, Henry F. Frierson, J. Carl Barrett, Charles L. Sawyers, John Tod Isaacs, Jin Tang Dong

Research output: Contribution to journalArticle

Abstract

Previous molecular genetic analyses identified a region of deletion at 13q21 in a variety of human cancers, suggesting the existence of a tumor suppressor gene(s) at this locus. In our earlier study on prostate cancer, the region of deletion was confined to a 3.1 cM interval between D13S152 and D13S162. At present, however, no known gene located in this interval has been firmly implicated in cancer, and the region remains too large for gene identification. To fine-map the area of interest, we established a contig of bacterial artificial chromosome (BAC) clones, narrowed the region of deletion by loss of heterozygosity (LOH) and homozygosity-mapping-of-deletion (HOMOD) analyses in different types of cancers, and tested a candidate gene from the region for mutation and alteration of expression in prostate cancers. The contig consisted of 75 overlapping BAC clones. In addition to the generation of 47 new sequence-tagged-site (STS) markers from the ends of BAC inserts, 76 known STS and expressed sequence tag markers were mapped to the contig (25 kb per marker on average). The minimal region of deletion was further defined to be about 700 kb between markers D13S791 and D13S166 by LOH analysis of 42 cases of prostate cancer, and by HOMOD analysis of eight prostate cancer cell lines/xenografts and 49 cell lines from cancers of the breast, ovary, endometrium, and cervix, using 18 microsatellite markers encompassing the deletion region. A gene that is homologous to the WTI tumor suppressor gene, AP-2rep (KLF12), was mapped in this region and was analyzed for its expression and genetic mutation. In addition to low levels of expression in both normal and neoplastic cells of the prostate, this gene did not have any mutations in a group of aggressive prostate cancers and cell lines/xenografts, as assessed by the methods of polymerase chain reaction-single strand conformational polymorphism analysis and direct sequencing. These studies suggest that a 700 kb interval at 13q21 harbors a tumor suppressor gene(s) that seems to be involved in multiple types of cancer, and that the AP-2rep gene is unlikely to be an important tumor suppressor gene in prostate cancer. The BAC contig and high-resolution physical map of the defined region of deletion should facilitate the cloning of a tumor suppressor gene(s) at 13q21.

Original languageEnglish (US)
Pages (from-to)333-344
Number of pages12
JournalGenes Chromosomes and Cancer
Volume31
Issue number4
DOIs
StatePublished - 2001

Fingerprint

Bacterial Artificial Chromosomes
Tumor Suppressor Genes
Prostatic Neoplasms
Sequence Tagged Sites
Genes
Neoplasms
Loss of Heterozygosity
Heterografts
Cell Line
Mutation
Clone Cells
Expressed Sequence Tags
Endometrium
Cervix Uteri
Microsatellite Repeats
Ovarian Neoplasms
Organism Cloning
Prostate
Molecular Biology
Breast Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Chen, C., Brabham, W. W., Stultz, B. G., Frierson, H. F., Carl Barrett, J., Sawyers, C. L., ... Dong, J. T. (2001). Defining a common region of deletion at 13q21 in human cancers. Genes Chromosomes and Cancer, 31(4), 333-344. https://doi.org/10.1002/gcc.1152

Defining a common region of deletion at 13q21 in human cancers. / Chen, Ceshi; Brabham, Will W.; Stultz, Brian G.; Frierson, Henry F.; Carl Barrett, J.; Sawyers, Charles L.; Isaacs, John Tod; Dong, Jin Tang.

In: Genes Chromosomes and Cancer, Vol. 31, No. 4, 2001, p. 333-344.

Research output: Contribution to journalArticle

Chen, C, Brabham, WW, Stultz, BG, Frierson, HF, Carl Barrett, J, Sawyers, CL, Isaacs, JT & Dong, JT 2001, 'Defining a common region of deletion at 13q21 in human cancers', Genes Chromosomes and Cancer, vol. 31, no. 4, pp. 333-344. https://doi.org/10.1002/gcc.1152
Chen C, Brabham WW, Stultz BG, Frierson HF, Carl Barrett J, Sawyers CL et al. Defining a common region of deletion at 13q21 in human cancers. Genes Chromosomes and Cancer. 2001;31(4):333-344. https://doi.org/10.1002/gcc.1152
Chen, Ceshi ; Brabham, Will W. ; Stultz, Brian G. ; Frierson, Henry F. ; Carl Barrett, J. ; Sawyers, Charles L. ; Isaacs, John Tod ; Dong, Jin Tang. / Defining a common region of deletion at 13q21 in human cancers. In: Genes Chromosomes and Cancer. 2001 ; Vol. 31, No. 4. pp. 333-344.
@article{036204095b06477ba151f844e8cb2714,
title = "Defining a common region of deletion at 13q21 in human cancers",
abstract = "Previous molecular genetic analyses identified a region of deletion at 13q21 in a variety of human cancers, suggesting the existence of a tumor suppressor gene(s) at this locus. In our earlier study on prostate cancer, the region of deletion was confined to a 3.1 cM interval between D13S152 and D13S162. At present, however, no known gene located in this interval has been firmly implicated in cancer, and the region remains too large for gene identification. To fine-map the area of interest, we established a contig of bacterial artificial chromosome (BAC) clones, narrowed the region of deletion by loss of heterozygosity (LOH) and homozygosity-mapping-of-deletion (HOMOD) analyses in different types of cancers, and tested a candidate gene from the region for mutation and alteration of expression in prostate cancers. The contig consisted of 75 overlapping BAC clones. In addition to the generation of 47 new sequence-tagged-site (STS) markers from the ends of BAC inserts, 76 known STS and expressed sequence tag markers were mapped to the contig (25 kb per marker on average). The minimal region of deletion was further defined to be about 700 kb between markers D13S791 and D13S166 by LOH analysis of 42 cases of prostate cancer, and by HOMOD analysis of eight prostate cancer cell lines/xenografts and 49 cell lines from cancers of the breast, ovary, endometrium, and cervix, using 18 microsatellite markers encompassing the deletion region. A gene that is homologous to the WTI tumor suppressor gene, AP-2rep (KLF12), was mapped in this region and was analyzed for its expression and genetic mutation. In addition to low levels of expression in both normal and neoplastic cells of the prostate, this gene did not have any mutations in a group of aggressive prostate cancers and cell lines/xenografts, as assessed by the methods of polymerase chain reaction-single strand conformational polymorphism analysis and direct sequencing. These studies suggest that a 700 kb interval at 13q21 harbors a tumor suppressor gene(s) that seems to be involved in multiple types of cancer, and that the AP-2rep gene is unlikely to be an important tumor suppressor gene in prostate cancer. The BAC contig and high-resolution physical map of the defined region of deletion should facilitate the cloning of a tumor suppressor gene(s) at 13q21.",
author = "Ceshi Chen and Brabham, {Will W.} and Stultz, {Brian G.} and Frierson, {Henry F.} and {Carl Barrett}, J. and Sawyers, {Charles L.} and Isaacs, {John Tod} and Dong, {Jin Tang}",
year = "2001",
doi = "10.1002/gcc.1152",
language = "English (US)",
volume = "31",
pages = "333--344",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Defining a common region of deletion at 13q21 in human cancers

AU - Chen, Ceshi

AU - Brabham, Will W.

AU - Stultz, Brian G.

AU - Frierson, Henry F.

AU - Carl Barrett, J.

AU - Sawyers, Charles L.

AU - Isaacs, John Tod

AU - Dong, Jin Tang

PY - 2001

Y1 - 2001

N2 - Previous molecular genetic analyses identified a region of deletion at 13q21 in a variety of human cancers, suggesting the existence of a tumor suppressor gene(s) at this locus. In our earlier study on prostate cancer, the region of deletion was confined to a 3.1 cM interval between D13S152 and D13S162. At present, however, no known gene located in this interval has been firmly implicated in cancer, and the region remains too large for gene identification. To fine-map the area of interest, we established a contig of bacterial artificial chromosome (BAC) clones, narrowed the region of deletion by loss of heterozygosity (LOH) and homozygosity-mapping-of-deletion (HOMOD) analyses in different types of cancers, and tested a candidate gene from the region for mutation and alteration of expression in prostate cancers. The contig consisted of 75 overlapping BAC clones. In addition to the generation of 47 new sequence-tagged-site (STS) markers from the ends of BAC inserts, 76 known STS and expressed sequence tag markers were mapped to the contig (25 kb per marker on average). The minimal region of deletion was further defined to be about 700 kb between markers D13S791 and D13S166 by LOH analysis of 42 cases of prostate cancer, and by HOMOD analysis of eight prostate cancer cell lines/xenografts and 49 cell lines from cancers of the breast, ovary, endometrium, and cervix, using 18 microsatellite markers encompassing the deletion region. A gene that is homologous to the WTI tumor suppressor gene, AP-2rep (KLF12), was mapped in this region and was analyzed for its expression and genetic mutation. In addition to low levels of expression in both normal and neoplastic cells of the prostate, this gene did not have any mutations in a group of aggressive prostate cancers and cell lines/xenografts, as assessed by the methods of polymerase chain reaction-single strand conformational polymorphism analysis and direct sequencing. These studies suggest that a 700 kb interval at 13q21 harbors a tumor suppressor gene(s) that seems to be involved in multiple types of cancer, and that the AP-2rep gene is unlikely to be an important tumor suppressor gene in prostate cancer. The BAC contig and high-resolution physical map of the defined region of deletion should facilitate the cloning of a tumor suppressor gene(s) at 13q21.

AB - Previous molecular genetic analyses identified a region of deletion at 13q21 in a variety of human cancers, suggesting the existence of a tumor suppressor gene(s) at this locus. In our earlier study on prostate cancer, the region of deletion was confined to a 3.1 cM interval between D13S152 and D13S162. At present, however, no known gene located in this interval has been firmly implicated in cancer, and the region remains too large for gene identification. To fine-map the area of interest, we established a contig of bacterial artificial chromosome (BAC) clones, narrowed the region of deletion by loss of heterozygosity (LOH) and homozygosity-mapping-of-deletion (HOMOD) analyses in different types of cancers, and tested a candidate gene from the region for mutation and alteration of expression in prostate cancers. The contig consisted of 75 overlapping BAC clones. In addition to the generation of 47 new sequence-tagged-site (STS) markers from the ends of BAC inserts, 76 known STS and expressed sequence tag markers were mapped to the contig (25 kb per marker on average). The minimal region of deletion was further defined to be about 700 kb between markers D13S791 and D13S166 by LOH analysis of 42 cases of prostate cancer, and by HOMOD analysis of eight prostate cancer cell lines/xenografts and 49 cell lines from cancers of the breast, ovary, endometrium, and cervix, using 18 microsatellite markers encompassing the deletion region. A gene that is homologous to the WTI tumor suppressor gene, AP-2rep (KLF12), was mapped in this region and was analyzed for its expression and genetic mutation. In addition to low levels of expression in both normal and neoplastic cells of the prostate, this gene did not have any mutations in a group of aggressive prostate cancers and cell lines/xenografts, as assessed by the methods of polymerase chain reaction-single strand conformational polymorphism analysis and direct sequencing. These studies suggest that a 700 kb interval at 13q21 harbors a tumor suppressor gene(s) that seems to be involved in multiple types of cancer, and that the AP-2rep gene is unlikely to be an important tumor suppressor gene in prostate cancer. The BAC contig and high-resolution physical map of the defined region of deletion should facilitate the cloning of a tumor suppressor gene(s) at 13q21.

UR - http://www.scopus.com/inward/record.url?scp=0034932249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034932249&partnerID=8YFLogxK

U2 - 10.1002/gcc.1152

DO - 10.1002/gcc.1152

M3 - Article

C2 - 11433524

AN - SCOPUS:0034932249

VL - 31

SP - 333

EP - 344

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

IS - 4

ER -